Sponsorship of ESTIV Congress is an excellent way to keep your company’s name out front. We offer Gold, Silver, Bronze, and Exhibitor levels. In addition, you can also choose from a variety of A-La-Carte Sponsorship opportunities, in case you do not wish to exhibit.
Why Sponsor?
- Support the scientists pursuing the NAMs concepts
- Put your Business in the Spotlight
- Get your Brand Noticed
- New Clients, New Customers, New Business
- Market your Business Inexpensively
- Develop your Products and Services
- Find Vendors and Solution Providers
❓ Questions
If you have any queries or if you need further information about the sponsor and exhibitor packages, please contact the congress secretariat via:
estiv@klinkhamergroup.com.
Interested?
Registering as a sponsor is quick and easy through our online module. Just click the button below!
A BIG THANK YOU TO OUR CONFIRMED SPONSORS:
Gold sponsor
Bronze sponsors
Exhibitors and supporters
L’Oreal Research & Innovation
At L’Oréal, we are committed for beauty with no animal testing.
L’Oréal Groupe continuously invests in the development of non-animal testing methods and rallies the scientific communities in this journey. We share our scientific advances, knowledge and expertise to foster the use of non-animal testing methods, while engaging with regulators and decision makers to cease animal testing for cosmetics everywhere in the world.
Click here for more information: https://www.loreal.com/en/commitments-and-responsibilities/for-the-planet/for-beauty-with-no-animal-testing/
INVITROLIZE
Early detection of the potential hazard of inhalable chemicals and materials with a focus on respiratory sensitization Get peace of mind with ALIsens®, our award-winning patented technology. Our human cell-line based in vitro models allow for the first time the identification and differentiation of respiratory sensitizers and respiratory irritants under realistic air-liquid interphase exposure conditions. The obtained results will give you information on the hazard that a certain tested chemical has the potential to induce respiratory sensitization. The results can guide your product development to select molecules with lower hazard or support registration dossiers.
Nikon Europe
The Nikon BioImaging Lab offers contract research services for microscopy-based imaging and analysis tailored to biotech, pharma, and research communities. We excel in four key areas: Speed – Advanced imaging hardware and expertise enable rapid setup, while in-house cell culture capabilities streamline assay development. Quality – Backed by over 100 years of Nikon’s leadership in optical and digital imaging, we deliver versatile, high-performance solutions. Reproducibility – Precision hardware and custom software ensure low variability and exceptional accuracy. Flexibility – Custom configurations meet diverse imaging needs. Our expert team provides cell culture, sample preparation, data acquisition, and analysis, supporting your research goals.
VITROCELL Systems GmbH
VITROCELL® is specialized in the development of advanced in vitro exposure systems for inhalation toxicology: mammalian cells can be exposed to gases, environmental atmospheres, nano particles and complex mixtures at the air/liquid interface. VITROCELL® Skin modules and autosamplers are designed for the exposure of tissue. Our customers are leading research institutes, contract research organizations, regulatory authorities as well as the pharmaceutical and other industries throughout the world.
Toxys
Toxys is a global leading expert that develops NAMs and offers a broad spectrum of animal-free laboratory tests for the safety assessment of novel medicines, chemicals, cosmetics, and food. We are experts in the fields of genetic, developmental, and investigative toxicology. Our unique assays are developed with the focus on understanding the mode-of-action of toxic compounds and include ToxTracker, ReproTracker, and ToxProfiler. Toxys is currently working with most of the top 10 global pharma companies and major chemical, cosmetics, and food multinationals.
International Collaboration on Cosmetics Safety
The International Collaboration on Cosmetics Safety (ICCS) is a global initiative focused on advancing the adoption of animal-free safety assessment approaches for cosmetics, personal care products and their ingredients. ICCS is comprised of 42 international members including cosmetic product manufacturers and their suppliers, industry associations, and animal protection organizations all working together to drive greater global awareness to accelerate widespread use of animal-free assessments through research, education, and regulatory engagement.
BiomimX Srl
BiomimX S.r.l. is a pioneer in Organ on a Chip (OoC) technology, producing the next generation of clinically relevant in-vitro models for pharmaceutical drug discovery and testing. Our proprietary platform integrates microfluidics, 3D cell culture, live human cells, and mechanical stimuli to produce “Beating Organs on a Chip” . These recapitulate, with unprecedented precision and predictability, clinically relevant models reflective of human physiology and pathology. Pharma R&D is an area where animal models continue to fall short due to lack of translatability and/or lack of relevant models. Regulatory agencies in the US and Europe are now moving forward to encourage biopharma’s use of more predictive non-animal models. BiomimX is poised to be a leader in this space and has gained early traction with industry. Every tissue in the body is subject to motion. The advantage of BiomimX approach is our patented uBeat® platform which provides 3D microtissues with controlled mechanical stimulation. Current competitors are limited to 2D cultures without mechanical stimulation and poor scalability. Our models overcome this with 3D culture, mechanical stimulation, and materials allowing for enhanced scalability. This provides a window into human organs and complex disease, without involving animals. The result is a more reliable, responsive, and predictive in vitro model to investigate new therapies. BiomimX lead model is uHeart (Visone, Tox Sciences, 2023; +4 additional cardiac publications), a functional beating heart on a chip for cardiotoxicity and safety testing early in the pipeline. uHeart was recently qualified with 12 drugs as a predictor of functional cardiotoxicity, showing 83.3% sensitivity, 100% specificity, and 91.6% accuracy. Our pipeline includes a range of predictive physiological and pathological models. uKnee (Occhetta, Nature Biomed Eng, 2019; +2 additional OA publications) has successfully supported a recent IND. Other key models include uScar (fibrosis; Visone, Adv Health Mat, 2023), uGut (Ballerini, Nature Biomed Eng, 2025), uLung and uLiver-Heart (Ferrari, Adv Mat Tech, 2023). The company’s founders have deep expertise in microfluidics, microtechnology, translational science, and advanced 3D in-vitro cell culture technologies. Founding members also serve in academia and notable leadership roles for key societies in the field, including Chair and Board Member of the European Organ on Chip Society. In addition, they are currently communicating with the EMA regarding BiomimX models. They have over 20+ publications in the field and a strong track record of EU grant success aimed at forwarding the field of OoC. The company is revenue producing with global biopharma and CROs as clients and aims to revolutionize the way new drugs are tested.
LifeNet Health LifeSciences
LifeNet Health LifeSciences gives healing every advantage by providing research solutions that empower groundbreaking discoveries around the world. Our goal is to improve health and safety for humankind by providing all-human cells, in vitro physiological systems, biospecimens for research, and cytotoxicity services. We support scientists in the pharmaceutical, biotech, agriscience, food safety, and cosmetic industries.
Primacyt Cell Culture Technology GmbH
PRIMACYT develops, produces and distributes biological in vitro assay systems for testing of chemicals in human and animal health and environmental safety. We offer one of the world’s most comprehensive portfolios of liver related products obtained from human and animal species like birds, fresh and seawater fish, rodents, and farm animals. We produce primary human and animal cells, liver subcellular fractions, ex vivo full thickness and/or dermatomed human skin explants, blood derived cells, and consumables for applications in preclinical testing and product development in human and animal health and environmental safety evaluations. Products are manufactured in accordance with OECD test guidelines. We are GLP certified, offer medical device testing services and act as a reference laboratory for the European Union.
NAMWISE
The overarching aim of NAMWISE project is to encourage and facilitate the uptake of NAMs (New Approach Methodologies) by providing a defined set of recommendations with concrete guidance and associated training resources on how effectively validate, integrate, and use NAMs for the assessment of the safety and efficacy of chemicals and pharmaceuticals. The NAMWISE project adopts the NAM definition with the maximum leverage for driving the paradigm shift in (eco)toxicology: a definition that does not rely on live non-human vertebrate animals including independently feeding larval forms; and foetal forms of mammals as from the last third of their normal development, and live cephalopods (as defined by the directive 2010/63/EU). The NAMWISE project will explore how, one NAM or a combination of NAMs, can be used to fulfill regulatory requirements for chemicals/pharmaceuticals safety and drug efficacy.
According to this definition the project will focus on the NAM expertise characterizing its consortium: in vitro including organoids and organ-on-chips, and in silico approaches, Adverse Outcome Pathways (AOP) and Integrated Approaches to Testing and Assessment (IATA). In line with existing European initiatives, the project will gather outcomes and identify potential shortcomings, propose solutions and recommendations for the next EU roadmap to phase out regulatory animal testing.
STEMCELL Technologies
DNTOX GmbH
DNTOX specializes in animal experiment-free neurotoxicity testing services for the chemical and pharmaceutical industry. Our expertise lies in the assessment of potential harms of chemical substances to the developing or adult brain. By combining unique human cell-based 2D and 3D test systems with state-of-the-art machine learning technology, we provide a faster, more cost-effective and more human-relevant alternative to traditionally used rodent studies. In addition to the use for regulatory purposes, our cost- and time-effective tests can be implemented as a routine screening during the development of new chemicals and pharmaceuticals. Our clients can thus protect their investments by mitigating the risk of a late-stage safety-related dropout of new developments. By facilitating the development of chemicals that are safe and sustainable by design, our innovative services contribute to the protection of public health and the EU Chemicals Strategy for Sustainability Towards a Toxic-Free Environment, which is a key commitment of the European Green Deal.
Japan Tissue Engineering Co., Ltd
| J-TEC offers LabCyte, reconstructed human tissue models as alternatives to animal testing, leveraging its advanced cell culture technology based on the expertise of providing high quality regenerative medical products. – LabCyte EPI-MODEL：Reconstructed human epidermis, listed in OECD TG439 skin irritation test, TG431 skin corrosion test, and TG442D skin sensitization test (EpiSensA). – LabCyte CORNEA-MODEL: Reconstructed human corneal epithelium, listed in OECD TG492 eye irritation test. LabCyte has a structure and morphology that parallels those of human tissues, supporting experiments in highly physiological conditions. J-TEC has commercialized 5 regenerative medical products in Japan (autologous cultured epidermis, cartilage, etc.). Utilizing the cell culture technology developed by the late Prof. Howard Green of Harvard Medical School, we have built an advanced manufacturing and quality control system, stably supplying regenerative medical products for years. |
Galatek GmbH
Galatek GmbH delivers AI-driven lab automation and integrated instrumentation/software solutions designed to accelerate scientific discovery. We build end-to-end workflows that combine robotics, smart devices, and orchestration software to improve throughput, quality, and traceability in R&D and manufacturing. We provide both standalone and integrated automation systems, as well as advanced intelligent software, including liquid handling workstations, high-content imaging platforms, and integrated automation for organoid culture, drug screening, synthetic biology, and multi-omics. Galatek is headquartered in Munich, Germany, where we operate a demonstration center and warmly welcome customers to visit.
ToxMinds BV
ToxMinds BV is a product safety and regulatory compliance consultancy headquartered in Brussels and a subsidiary office in Bangalore. Its team of consultants serve clients from the cosmetics, chemical, and pharmaceutical industries. Passionate about toxicology and leveraging emerging new approach methodologies, the team supports customers in bringing safe, regulatory-compliant, and sustainable products to market. The ToxMinds team is specialised in identifying assessment and testing strategies to fill safety information gaps without any further animal testing. ToxMinds has a proven track record for successful submissions of risk assessments under existing cosmetics, chemicals, biocides, and medicinal product regulatory frameworks.
PhoenixBio
PhoenixBio is a global leader in the development and distribution of high-qualityhuman liver models. Our PXB-Mouse® is a humanized liver animal model and has aliver repopulated with up to 98% human hepatocytes. PXB-cells® are humanhepatocytes freshly isolated from the PXB-mouse and are frequently applied for invitro research. PhoenixBio models accelerate pharmaceutical and chemicalcompound development due to their unique ability to deliver preclinical insights thatare more predictive of human outcomes. Our models are applied in several research
acCELLerate
acCELLerate is a specialist for large-scale preparation of Assay Ready Cell Banks for small molecule drug discovery (HTS), ADME-Tox, and potency testing of biotherapeutics. Assay Ready Cells are used instantly after thawing without prior cultivation – basically like a reagent. This approach increases the flexibility and improves the precision of a cell-based bioassay.
ETB-BISLIFE
VitalTissue started in 2024 as a new division of the non-profit organisation Stichting ETB-BISLIFE. With the support of a startup grant by ZonMw and Stichting Proefdiervrij, we aim to successfully implement VitalTissue as a new division in ETB-BISLIFE within 3-5 years and become the infrastructure for the use of vital human residual tissue in scientific research in The Netherlands. We operate with integrity in a transparent, independent and reliable way. Often, not all tissue that is removed in surgery is needed for diagnostics and/or follow-up research. This residual tissue is usually destroyed. That is a pity, because human residual tissue offers great opportunities for scientific research to improve and accelerate drug development. VitalTissue makes this fresh tissue accessible to researchers in The Netherlands for existing and the development of new experimental models that better match human biology. As a consequence progression in medical research will be accelerated and dependence on animal testing will be reduced.
3Brain AG
3Brain is the first company to record cell activity with intelligent cell culture plates, merging microelectronics and biology to revolutionize life science research. With over two decades of innovation, we develop microchip-based technologies that optimize experiments, enhance statistical significance, and accelerate discoveries. Headquartered near Zürich, with branches in Genova and the US, we empower researchers worldwide to advance medical treatments and improve lives.
Institute for In Vitro Sciences (IIVS)
A nonprofit research and testing laboratory dedicated to the advancement of in vitro methods worldwide. Our familiarity with an array of different in vitro test systems enables us to provide contract testing services using the optimum assays to answer specific product safety and efficacy questions. Our laboratory team has experience in conducting in vitro assay validation studies, and providing hands-on training to an international audience.
CN Bio
CN Bio is on a mission to accelerate drug discovery. As a leading Organ-on-chip (OOC) company, the team is transforming how human-specific efficacy and safety data are generated. CN Bio’s human organ models deepen the understanding of disease mechanisms, help uncover new drug targets and enable effective therapeutics to be developed safely. Throughout the discovery and development process, the Company’s portfolio of accessible products and contract research services help save time and reduce costs. Based in Cambridge (UK), CN Bio brings over a decade of experience and know-how to engineering single and multi-organ microphysiological systems (MPS). The Company’s easy to adopt, adapt and scale PhysioMimix® platform accurately mimics human physiology in the laboratory. Using advanced, predictive in vitro human organ models, PhysioMimix enables the development of novel therapeutics with increased efficiency, whilst relieving the dependence on animal models. These models also offer valuable insights into how drugs will perform in patients, greatly reducing risks in the clinic.The power of PhysioMimix® technology has been recognized by the US FDA, resulting in the first co- publication between a drug regulator and an MPS provider and has been harnessed by 16 of the leading pharmaceutical companies. In 2023, CN Bio helped deliver a regulatory world first, when the Company supported Inipharm’s INI-822 successful filing to initiate clinical testing for the treatment of metabolic liver disease treatment.
Epithelix
Epithelix is a leading biotechnology company specializing in advanced tissue engineering solutions for the in vitro evaluation of drug efficacy and safety on the human respiratory tract. As a pioneer in New Approach Methodologies (NAMs), Epithelix delivers reliable, human-relevant alternatives to animal testing.
Leveraging a proprietary technology, Epithelix has developed long-term, fully differentiated human primary airway tissues that closely replicate in vivo physiology. The company offers a portfolio of ready-to-use respiratory models, including nasal, tracheal, bronchial (MucilAir™), small-airway (SmallAir™), and alveolar (AlveolAir™) epithelia, as well as advanced immunocompetent systems incorporating macrophages, neutrophils, or dendritic cells and a panel of primary human frozen cells.
In addition to its product offering, Epithelix provides expert contract research services (CRO), delivering a broad range of standard or tailored in vitro assays. Applications span toxicity and safety assessment, disease modelling such as asthma, cystic fibrosis, and COPD, as well as viral and bacterial infection, drug permeability, and efficacy testing of innovative therapeutic approaches -accelerating the development of safer and more effective respiratory medicines.
Website
Company page LinkedIn
Contact person via LinkedIn
Tecan
Tecan is a leading global provider of automated laboratory instruments and solutions. Our systems and components help people working in clinical diagnostics, basic and translational research and drug discovery bring their science to life.
Insilica
Insilica helps toxicologists address the capacity crisis with defensible, auditable, AI-accelerated assessments.
We build AI-powered platforms that automate chemical risk assessment. Our flagship product, ToxIndex, uses agentic workflows to orchestrate literature analysis, database retrieval, metabolism modeling, and property prediction — generating regulatory-grade toxicology reports in days instead of months. Sysrev, our collaborative evidence review platform, combines LLM-powered extraction with human expert validation, serving users across government agencies, industry, and academic institutions. BioBricks provides 200+ curated toxicological datasets powering predictive models trained over 1 billion triples.
Centre of Experimental Medicine (CEM)
The Centre of Experimental Medicine (CEM) of the Slovak Academy of Sciences (SAS) was established on 1 January 2018 by merging of the Institute of Experimental Pharmacology and Toxicology, the Institute of Normal and Pathological Physiology and the Institute of Heart Research into one Centre. CEM is focused on the integrated research into the causes, mechanisms of development and possibilities of prevention, diagnosis and treatment of societally important diseases with the emphasis on diseases of the cardiovascular and the nervous systems, metabolic disorders, mental disorders and mental health problems as well as diseases originating in the prenatal and early postnatal developmental periods. The research in CEM is carried out on in silico, in vitro, ex vivo and in vivo models with the aim to transfer the acquired knowledge to clinical practice. An important part is the evaluation of the effects of bioactive natural substances, their derivatives and original synthetic substances with pharmacotherapeutic potential, animal models of human diseases as well as the study of side-effects of toxic and chemical agents and radiation.
Dynamic42 GmbH
Dynamic42 GmbH provides immunocompetent, physiological organ-on-chip models combining ISO-certified, medical-grade standards with ease of use for scientists. As a spin-off from the University Hospital Jena in Germany, the company has developed a strong background in disease and infection modeling. Dynamic42 offers contract research for preclinical drug evaluation in human models of the vasculature, liver, intestine, lung and cancer as well as customized model development. The company further is producer of the DynamicOrgan® System the open organ-on-chip platform, provides a variety of medical-grade, low drug adsorption biochips and hands-on as well as online training courses within their Dynamic42 Academy.
PEPPER
Pepper is the Public Private Platform for the Pre-validation of Endocrine Disruptors (EDs) Characterization Methods. Created in 2019, Pepper is a public private partnership and non-profit association under French law, and has an original mode of governance. Pepper innovates in bringing together public authorities, various industries, federations, risk assessment agencies, NGOs and trade unions, and in adopting a pragmatic approach to fund validation. Pepper describes itself as a validation manager and accelerator at the service of all parties involved. It aims at identifying and documenting test methods of identification of EDs, organizing tests on these methods by test laboratories, and proposing validated methods fulfilling the required criteria to international validation authorities. From the start, Pepper has had a European dimension, reflected in funding, partnerships, and method developers and laboratories supported by Pepper. Today, more than 70 experts are involved in its work.
Alternatives Research & Development Foundation (ARDF)
–
Mattek In Vitro Life Science Laboratories s.r.o.
MatTek Life Sciences is at the forefront of tissue engineering technology and its lab-grown human tissues of the skin, eye, respiratory, and digestive systems are used worldwide as ethical and human-relevant alternatives to animal testing. MatTek tissues have unparalleled reproducibility, as well as multiple regulatory acceptances and validations from organizations like the OECD, ISO, and US EPA to predict the irritation, corrosion, and photosensitivity potential of chemical, pharmaceutical, cosmetic, and other skin care products. Product formulation scientists in the cosmetic, personal care, chemical, and pharmaceutical industries choose MatTek tissues for their unique ability to deliver human-relevant responses that are more predictive of clinical outcomes. Mattek is now Part of Sartorius.
IVTech srl
IVTech is an Italian biotech company, founded in 2014, at that time as a spin-off of the University of Pisa.
The company develops and commercializes fluidic platforms to develop 5D in-vitro models. In the last 10 years of activities, we have structured IVTech, in order to meet clients and satisfy their problems with an easy to use and versitile technology.
Now we are ready to launch our new products and services to support the diffusion of NAMs.